Evidence map›Paper›PMID 21612930›Full record

ArticleBioorganic & medicinal chemistry2011

Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.

Ali Azhdarinia, Nathaniel Wilganowski, Holly Robinson, Pradip Ghosh, Sunkuk Kwon, Zawaunyka W Lazard, Alan R Davis, Elizabeth Olmsted-Davis, Eva M Sevick-Muraca

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Advancing theranostics with tumor-targeting peptides for precision otolaryngology.World journal of otorhinolaryngology - head and neck surgery · 2016
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ali AzhdariniaCenter for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, TX 77030, USA. ali.azhdarinia@uth.tmc.edu
Nathaniel Wilganowski
Holly Robinson
Pradip Ghosh
Sunkuk Kwon
Zawaunyka W Lazard
Alan R Davis
Elizabeth Olmsted-Davis
Eva M Sevick-Muraca
The University of Texas Health Science Center at Houston · USBaylor College of Medicine · USBrown Foundation · US

Funding

Fluorescence enhanced optical tomographyR01CA135673 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SEVICK, EVA M. · 2008 to 2012
$1.5M
NCI NIH HHS R01 CA135673
6 · The paper itself

Abstract

Optical imaging possesses similar sensitivity to nuclear imaging and has led to the emergence of multimodal approaches with dual-labeled nuclear/near-infrared (NIR) agents. The growing impact of (68)Ga (t(1/2)=68 min) labeled peptides on preclinical and clinical research offers a promising opportunity to merge the high spatial resolution of NIR imaging with the clinically-accepted positron emission tomography (PET). Previously, dual-labeled agents have been prepared with longer-lived radiometals and showed no detrimental effects on optical properties as a result of radiolabeling. In this study, we selected a peptide (M(2)) that targets MMP-2/9 and is dual-labeled with IRDye 800 CW and (68)Ga. Since (68)Ga chelation typically requires low pH (3.5-4) and elevated heating temperatures (95 °C), we sought to evaluate the impact of (68)Ga labeling on the optical properties of M(2). An efficient method for preparation of (68)Ga-M(2) was developed and reaction conditions were optimized. Stability studies in PBS, DTPA, and serum were performed and high levels of intact agent were evident under each condition. The addition of multiple reporters to a targeting agent adds further complexity to the characterization and validation and thus requires not only testing to ensure the agent is stable chemically and radiochemically, but also optically. Therefore, fluorescence properties were evaluated using a spectrofluorometer as well as by fluorescence detection via HPLC. It was determined that (68)Ga-labeling conditions did not impair the fluorescent properties of the agent. The agent was then used for in vivo imaging in a mouse model of heterotopic ossification (HO) with activated MMP-9 expression as an early biomarker which precedes mineralization. Although (68)Ga-complexation greatly reduced binding affinity of the peptide and negated tracer uptake on PET, NIR imaging showed consistent fluorescent signal that correlated to MMP-9 expression. This attests to the feasibility of using (68)Ga/NIR for dual-labeling of other peptides or small molecules for multimodality molecular imaging.

Indexed as

AnimalsChromatography, High Pressure LiquidDrug Delivery SystemsFluorescent DyesGallium RadioisotopesHumansMatrix Metalloproteinase 9MiceMice, Inbred NODMice, SCIDMolecular StructurePeptidesFluorescent DyesGallium RadioisotopesMatrix Metalloproteinase 9Peptides

Identifiers

PMID21612930
PMCPMC3148023
OpenAlexW1984417319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.